CONMED (CNMD)
(Delayed Data from NYSE)
$70.01 USD
-1.30 (-1.82%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $69.99 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Conmed (CNMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$111.13 | $132.00 | $98.00 | 55.84% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Conmed comes to $111.13. The forecasts range from a low of $98.00 to a high of $132.00. The average price target represents an increase of 55.84% from the last closing price of $71.31.
Analyst Price Targets (8 )
Broker Rating
Conmed currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, three are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 37.5% and 25% of all recommendations. A month ago, Strong Buy made up 37.5%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
2/1/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
2/1/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 8 |
Average Target Price | $111.13 |
LT Growth Rate | 25.40% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 63 of 252 |
Current Quarter EPS Est: | 0.74 |